Thiogenesis Therapeutics Corp (TTI)

[CommodityCoverage]

Thiogenesis Therapeutics is strategically advancing its lead compound, TTI-0102, through a robust pipeline of rare pediatric indications facing zero approved treatments.

Currently dosing MELAS patients in a Phase?2 trial for the orphan mitochondrial disorder, part of a MELAS market projected to reach nearly USD?494?million by 2035, TTI is additionally initiating a Phase?2a trial in Leigh Syndrome Spectrum in collaboration with CHOP (Children’s Hospital of Philadelphia), targeting a disease impacting roughly 1 in 40,000 newborns.

In parallel, the EMA’s CHMP has endorsed TTI's Phase?2a IMPD for pediatric MASH in children aged 10–17—an indication grounded in escalating pediatric fatty liver disease and supported by recent EU patent protection through 2038.

Check out the full pipeline here:
https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/

Posted on Behalf of Thiogenesis Therapeutics Corp.